CHILD HEALTH REVIEW PROTOCOL DRAFT

A SYSTEMATIC REVIEW AND META-ANALYSIS OF STUDIES EXAMINING THE RELATIONSHIP BETWEEN REPORTED RACISM AND HEALTH AND

WELLBEING FOR CHILDREN AND ADOLESCENTS.

Naomi Priest<sup>1, 2\*</sup>, Kate Doery<sup>1, 2</sup>, Mandy Truong<sup>3</sup>, Shuaijun Guo<sup>2,4</sup>, Brigid Trenerry<sup>5</sup>, Saffron Karlsen<sup>6</sup>, Yvonne Kelly<sup>7</sup>, Yin Paradies<sup>8</sup>

Australian National University, Centre for Social Research and Methods, Canberra, Australia

Murdoch Children's Research Centre, Population Health, Melbourne, Australia

Monash University, School of Nursing and Midwifery, Melbourne, Australia

University of Melbourne, Department of Pediatrics, Melbourne, Australia.

Singapore University of Technology and Design, Lee Kuan Yew Centre for Innovative Cities, Singapore

University of Bristol, School of Sociology, Politics and International Studies, Bristol, United Kingdom

University College London, Department of Epidemiology and Public Health, London, United Kingdom 7.

Deakin University, School of Humanities and Social Science, Melbourne, Australia

\* Corresponding Author Associate Professor Naomi Priest, The Australian National University, Canberra ACT

2600 Australia. Email: naomi.priest@anu.edu.au Phone: +61 2 6125 4849.

Word Count: 2794

**ABSTRACT** 

Introduction: There is a growing body of research showing associations between experiences of racism and poor

health and wellbeing outcomes for children and adolescents. The aim of this review protocol is to update the first

systematic review conducted by Priest et al. 2013, including a meta-analysis of findings. Based on previous

empirical data, it is anticipated that child and adolescent health will be negatively impacted by racism. This review

will provide updated evidence of effect sizes across outcomes and identify moderators and mediators of

relationships.

Methods and analysis: This systematic review and meta-analysis will include studies that explore associations

between experiences of racism and racial dissemination with health outcomes of children and adolescents aged 0-

24 years of age from any racial/ethnic/cultural group. Outcome measures include general health and wellbeing,

physical health, mental health, healthcare utilisation and health behaviours. Exposure measures include self-

reported and proxy reported personal experiences of racism and reported experiences of vicarious racism. The

authors will conduct a comprehensive search of studies from the earliest time available to September 2020. All

relevant studies will be screened with data extraction, quality appraisal and publication bias conducted

independently by at least two authors.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1

Ethics and Dissemination: This review will provide evidence for future research within the field and help to

support policy and practice development. Results from this systematic review and meta-analysis will be widely

disseminated to both academic and non-academic audiences.

Ethics approval is not required as this is a review of existing empirical findings.

Key Words: Protocol, Systematic-Review, Meta-analysis, Racism, Child Health.

**Article Summary** 

This is an updated systematic review which aims to update the findings from the first international review

conducted by Priest et al. 2013. However, it is the first meta-analysis to be conducted exploring the

relationship between racism and health in child and adolescent from all ethnic/racial/cultural

backgrounds.

This systematic review will show the health effects of racial discrimination on child and adolescent

health, the key pathways by which racial discrimination influences these outcomes and identify potential

moderators and mediators.

Findings from this systematic review and meta-analysis will be used to provide recommendations for

future research and inform the development of effective evidence-based strategies for addressing racism

and ameliorating its harmful effects.

This systematic review has a bias towards papers published in English as this review will only search

studies published in English, meaning that studies not-published in English will not be included in this

review. By doing so this review may not include all findings of all relevant studies.

INTRODUCTION

2

Racism and racial discrimination are widely recognised as critical determinants of health and health inequities for

children and adolescents across populations and contexts<sup>1-3</sup>. Racism is a system of oppression that categorises and

stratifies social groups into 'races', devalues and disadvantages those considered inferior and differentially

allocates to them valued societal resources and opportunities<sup>4 5</sup>. Racism is expressed across multiple levels,

including systemic and inter- and intra-personal levels, and operates in many forms including vicarious racism,

whereby individuals experience racism on a secondary level, witnessing or being informed of family, friends and

strangers experiencing racism<sup>67</sup>. Racial discrimination is the behavioural expression of racism and also manifests

at systemic and individual levels. Currently the world is currently experiencing two global pandemics, COVID-

19 and racism, with many people experiencing heightened levels of discrimination which is having negative

impacts on people' health and wellbeing8.

Research on racism and health has predominantly focused on interpersonal experiences, with considerable

evidence documenting negative health effects across multiple outcomes<sup>5 9 10</sup>. However, most of this evidence

remains focusing on adults, with far less research conducted among children and adolescents.

Priest et al. 1 conducted the first international systematic review of epidemiological studies on reported racial

discrimination and the health and wellbeing of children and adolescents, including 121 studies. However since

this report was published in 2013 the contribution of racism as a social determinant of health and wellbeing among

children and adolescents has received growing attention<sup>3</sup>. There is increasing evidence of the impact of racism on

pathophysiological processes (e.g. allostatic load and stress neurobiology) and biological markers (e.g. C-reactive

protein and cortisol)<sup>11</sup> as well as on sleep<sup>12-14</sup> among children and adolescents.

A recent review of vicarious racism and child health found 30 studies published up to May 2016 compared with

10 studies in the previous 2013 review (with studies searched up to November 2011)<sup>6</sup>. This represents a three-

fold increase in studies examining vicarious racism and child health in approximately four and a half years.

Additionally, our original review found that two-thirds of the included studies were published between 2005-

2012<sup>1</sup>. In light of the burgeoning research in the field, there is a need to review and reflect on the current evidence

to inform future scholarship in this area.

This present systematic review and meta-analysis aims to update findings from the 2013 review conducted by

Priest et al. An updated systematic review is necessary to include new data, new methods, and updated analysis

to a similar research question.<sup>15</sup> In this instance an updated systematic review is necessary due to changing social

policy and demographic contexts and new health priorities globally, as well as an increase in the number of recent

publications in this area, including in different country and population contexts. The first systematic review

identified that there were a limited number of longitudinal studies that have explored the health effects of racism

on children and a need to expand research in this area, with a focus needed on the complex pathways to which

child and youth health is impacted by experiences of racial discrimination<sup>1</sup>. Priest et al. called for an increase in

high-quality longitudinal research utilising robust multidimensional measures of racial discrimination<sup>1</sup>. As

highlighted since this review was published in 2013, there has been a large increase in the amount of research

3

being conducted in this field.

This present systematic review and meta-analysis will use the previous review as a guide, building upon it and

utilising an updated inclusion and exclusion strategy as well as expanding it to include a meta-analysis. As

indicated by Garner et al.<sup>15</sup> an updated systematic review can have an updated inclusion criteria whilst answering

a similar question.

The broad aims of this present systematic review and meta-analysis are:

To further understanding of the health effects of racial discrimination on child and adolescent health, the

key pathways by which racial discrimination influences these outcomes and identify potential moderators

and mediators.

To provide key recommendations for future research and inform the development of effective evidence-

based strategies for addressing racism and ameliorating its harmful effects.

**METHODS AND ANALYSIS** 

This systemic review and meta-analysis will follow the guidelines of the Preferred Reporting Items for Systematic

Reviews and Meta-Analysis (PRISMA)<sup>16</sup> with the PRISMA Protocols (PRISMA-P)<sup>17</sup> checklist followed for the

writing of this protocol and is included as appendix 1.

Progress on this systematic review and meta-analysis will be updated on the International Prospective Register

of Systematic Reviews (PROSPERO) to maintain transparency.

**Inclusion criteria** 

Studies using quantitative methods including cross-sectional; prospective and retrospective cohort; and case-

control designs will be included. Peer-reviewed journal articles (published or available as pre-prints), and

dissertations/theses will be included. We will also include grey literature including published reports. Studies that

do not report empirical associations between racism and child and adolescent health will not be included.

**Participants** 

4

Participants will include children and adolescents aged up to 24 years from any racial/ethnic/cultural groups. The

age range of participants has been updated since the previous review (which included participants up to 18 years)

due to a shift in the definition of the age of adolescence.<sup>18</sup>

**Exposure** 

This review will include studies which focus on reported childhood experiences of racism as the exposure,

including: self-reported racism, proxy reports from child's experiences or racism as reported by parents or carers

including experiences of vicarious racism (for example, witnessing racism experienced by family or friends).

There will be no restrictions placed on the timeframe of exposure to racism prior to the measurement.

Retrospective adult population studies that report on childhood experiences of racism will be noted, but will not

be included in our analysis.

**Outcome measures** 

Studies will be considered if they measure health outcomes in children and adolescents. Health and wellbeing

outcomes include measures of ill-health and illness as well as positive health outcomes across physical, mental

and behavioural domains. As guided by previous reviews and research 1912 19-24, the following health and wellbeing

outcomes will be included:

1. Pregnancy and birth outcomes (e.g. premature birth, low birth weight)

2. General health and wellbeing

Physical health (infectious disease and chronic conditions and markers e.g. body mass index, waist hip

ratio, blood pressure, metabolic and cardiovascular disease, overweight, obesity)

Mental health (e.g. social and emotional difficulties, psychological adjustment and distress, self-esteem,

mental illness, suicide risk, sleep difficulties, psychosis)

Wellbeing, life satisfaction, quality of life, resilience

6. Positive mental health (e.g. self-esteem, self-worth and resilience)

7. Learning and developmental difficulties (e.g. developmental delay, concerns about learning,

externalising behaviours such as violence etc., poor attachment etc.)

8. Health/risk behaviours (e.g. alcohol, tobacco, substance use)

9. Health care utilisation, healthcare costs, satisfaction with child health care system (use of screening tests,

5

maternal child health care, access to health care and treatment, adherence to treatment)

10. Biological markers (e.g. inflammation and cardiometabolic markers)

**Exclusion criteria** 

Studies reporting the effects of reported racism on other outcomes (e.g. education, employment) will not be

included. Studies where specific effects of racism cannot be isolated from broader measure of discrimination will

be noted but will not be included in the meta-analysis. Only studies published in English will be included.

Qualitative studies or studies only reporting the prevalence of racism without identifying associations with health

and wellbeing outcomes will not be included.

Data extraction and management

Search Strategy

The search strategy will be conducted in English and include studies from the earliest time available to September

2020. The search strategy will not be restricted to papers only published since the completion of the previous

search strategy in 2011 as databases regularly back index studies and therefore some studies may have been missed

by the original review. The search will be checked against the original search results to ensure that all studies that

have been back indexed are also included.

The search will be conducted in the Ovid Medline, Ovid PsycInfo, PubMed, ERIC and ProQuest (for

dissertation/theses) databases. Reference lists will also be hand-searched for relevant studies. The authors will

also search google scholar and key websites as well as contacting experts within the field to make sure all relevant

studies including grey literature are included.

The search will be performed using a string template combining search terms relevant to our study population,

exposure and outcomes. The search strategy template has been developed in consultation with medical library

staff utilising the previous search strategy by Priest et al. 1 as a template. The search template to be used for Medline

is included as appendix 2, which will be updated accordingly for each database.

Selection of studies

6

One member of the review team will conduct the initial search in the selected databases with the search results to

be imported into Endnote X9<sup>25</sup>, with duplicates and papers not in English to be deleted. All titles and abstracts of

studies identified in the search will be independently screened for eligibility for inclusion by members of the

review team using Covidence. Full text studies will be assessed for final inclusion. Any discrepancies between

members of the review team will be resolved by having a third member of the review team adjudicate the decision.

Rationale for exclusion of studies will be noted throughout the screening process with a PRISMA flowchart<sup>16</sup>

being used to show the full selection process of studies.

Further, studies with inappropriate and/or insufficient data to allow meta-analysis will be documented, but

excluded from the quantitative analysis.

Data Extraction

Once the full text studies have been identified, members of the review team will extract the data using Airtable<sup>26</sup>.

An independent member of the review team will compare and check for inconsistencies with discrepancies

resolved through discussion. Data from some studies may appear in multiple publications. If publications include

unique combinations of exposure and outcome variables they will be extracted as distinct data sets; meaning that

one study may be included in the meta-analysis multiple times as different data-sets due to its use of multiple

measures of health or racism.

Specifically, this review will examine the key characteristics of studies of reported racism and health and

wellbeing among children and adolescents including:

where and when studies have been conducted, the racial/cultural/ethnic background, age and gender of

study populations, study designs, sample sizes, and data sources used;

how reported racism is defined, how this exposure is measured in terms of method of administration,

content and time frames of exposure, targets and perpetrators of racism, reactions/responses to racism and

settings in which racism is experienced; and

the prevalence of reported racism and direction/magnitude/effect sizes of associations found between

reported racism and health across health outcomes, study and exposure characteristics and identify effect

moderator and mediators of these associations.

Data to be extracted will include: authors; year of publication; study aims; study design (including sampling

methods); definition of racism exposure measure (s) (including tools/instruments and psychometric properties

when applicable; method of administration including informant(s); content and time frames of exposure, targets

and perpetrators of racism, reactions/responses to racism and settings in which racism is experienced); health

outcome measures; measure of racial/cultural/ethnic background; study location (country/region); place of

residence (urban/rural), sample size; participant demographics (age, racial/cultural backgrounds, gender, religion,

education, socio-economic status, migration status); study findings; prevalence of self-reported racism including

7

exposure characteristics; nature of associations between self-reported racism and health and wellbeing outcomes

(including subgroup analysis when reported (mean, SD, effect size)); reactions and responses to racism;

confounders, effect moderator and mediators of these associations; study recommendations; and study

quality/critical appraisal.

Effect sizes such as coefficients and p-values for each health outcome will be extracted. Both unadjusted and

adjusted effect sizes will be extracted when available, and covariates included in models recorded. Only effect

sizes for children and adolescents will be extracted. Where an overall effect size is reported across a range of ages,

we will extract subgroup effect sizes when reported.

Assessment of study quality and bias

Studies included in the review will be critically appraised to determine the validity of the study's findings from

the known literature and to provide readers with the ability to make an informed decision on the quality of these

findings. The review team will use a variety of Critical Appraisal Tools, utilising tools that are most relevant to

the methods used in the study. We will utilise the Systematic Review Toolbox to assist with finding the most

appropriate tools.<sup>27</sup> These tools will include the Newcastle-Ottawa Scale<sup>28</sup> and the Joanna Briggs critical appraisal

tools appropriate to relevant study designs. Any discrepancies between quality ratings will be resolved through

discussion between members of the review team. The quality ratings will be used as a guide for data analysis and

meta-analysis.

The review team will also assess the publication bias of the included studies. The review team will use a variety

of measures to assess the publication bias of the included studies, these will include using the Risk Of Bias In

Non-randomized Studies - of Exposures (ROBINS-E) Tool<sup>29</sup>, an assessment tool under development which

assesses seven different domains of bias in exposure studies, <sup>30</sup> as included as Appendix 3.

**Analysis** 

8

Data that meet all inclusion criteria will first be summarised descriptively and then analysed statistically. Data

analysis will be conducted using Airtable<sup>26</sup>.

A descriptive summary with data tables will be produced to summarise the literature. Study characteristics will

be presented in summary tables across key variables (including their specific design, study details, sample size,

age and racial or ethnic background of participants, exposure and outcome measures included).

Although meta-analysis is planned this will only become apparent when extracted data are reviewed for feasibility.

If data is available we will conduct analyses of associations between racism and health for different health outcome

measures, and at different time points. If possible, we will use random-effects models to aggregate effect sizes.

Subgroup analyses will be conducted for age, gender and ethnicity if possible. To assess the heterogeneity of

studies, we will use the Q-statistic test and the  $I^2$  statistic. If the test for heterogeneity denoted as  $I^2$  (if  $I^2 \le 25\%$ ),

studies will be considered homogeneous.

**DISCUSSION** 

As this is an updated systematic review and meta-analysis, we expect that whilst there has been a significant

amount of recent research conducted in this space, we do not anticipate our findings to be vastly different from

our original review. This review and meta-analysis will incorporate studies with participants from all

ethnic/racial/cultural backgrounds, and studies will not be limited to any one country or geographic area, and in

doing so we anticipate to show that this is a problem facing not just one specific population but children globally.

That is, we expect the review to show that racism and racial discrimination negatively impact on multiple health

outcomes in children and adolescents from different ethnic/racial/cultural backgrounds and across contexts. We

expect an increase of research in outcomes not considered in the original review, including sleep and inflammatory

and immune biomarkers, as well as markers of epigenetic risk and cellular aging and of endocrine and hormonal

function. Increased attention on younger age groups, vicarious as well as direct exposure, longitudinal

associations, and populations and settings outside of the United States of America is also anticipated.

The world is currently facing two global pandemics, with high levels of racial discrimination being experienced

globally throughout the COVID-19 pandemic<sup>8</sup>, and racism has been drawing increased media attention. Exploring

the health effects of racism and discrimination is paramount. Due to the expectant increase in research surrounding

this topic, a key contribution of the current study is to conduct a meta-analysis, which was not able to be conducted

before. We expect that through this meta-analysis we will be able to show rigorous and robust evidence showing

the relationship between experiences of racism and health and wellbeing outcomes for children and adolescents.

As this is the first meta-analysis of these studies, it will provide an evidence base for future research exploring the

9

effect of racism and child health, as well as for policy development and service delivery.

ETHICS AND DISSEMINATION

Ethics approval is not required as this is a review of existing empirical findings and no primary data will be

collected throughout the research.

The results from this review will be disseminated in peer-review publications, conference presentations as well as

communicated more broadly through factsheets and summaries disseminated through academic institution press

release and policy and practice partners.

Progress on this systematic review and meta-analysis will be updated on the International Prospective Register of

Systematic Reviews (PROSPERO) (PROSPERO ID 184055) to maintain transparency.

**AUTHOR CONTRIBUTIONS** 

NP conceptualised the review and contributed to all aspects of the protocol. KD drafted the protocol, developed

the search strategy with medical librarians. MT, JG, BT, SK, YK and YP reviewed the protocol draft.

**FUNDING STATEMENT** 

Naomi Priest is supported by a NHMRC Career Development Fellowship APP1123677.

**COMPETING INTERESTS** 

The authors have no conflicts of interest relevant to this article to disclose.

REGISTRATION

10

The systematic review will be registered with PROSPERO, ID number 184055.

#### **REFERENCES**

- 1. Priest N, Paradies Y, Trenerry B, et al. A systematic review of studies examining the relationship between reported racism and health and wellbeing for children and young people. Social Science and Medicine 2013;95:115-27. doi: https://doi.org/10.1016/j.socscimed.2012.11.031
- 2. Trent M, Dooley DG, Douge J, et al. The Impact of Racism on Child and Adolescent Health. Pediatrics 2019;144(2) doi: https://doi.org/10.1542/peds.2019-1765
- 3. Diversity ACo. AAPA Statement on Race & Racism, 2019.
- 4. Bonilla-Silva E. Rethinking racism toward a structural interpretation. American Sociological Review 1997;62(3):465-80.
- 5. Williams DR. Race and health: basic questions, emerging directions. AnnEpidemiol 1997;7(5):322-
- 6. Heard-Garris NJ, Cale M, Camaj L, et al. Transmitting Trauma: A systematic review of vicarious racism and child health. Social Science & Medicine 2017;199:230-40. doi: https://doi.org/10.1016/j.socscimed.2017.04.018
- 7. Harrell SP. A multidimensional conceptualization of racism-related stress: implications for the well-being of people of color. American Journal of Orthopsychiatry 2000;70(1):42-57. doi: https://doi.org/10.1037/h0087722
- 8. Devakumar D, Selvarajah S, Shannon G, et al. Racism, the public health crisis we can no longer ignore. Lancet (London, England) 2020
- 9. Paradies Y, Ben J, Denson N, et al. Racism as a Determinant of Health: A Systematic Review and Meta-Analysis. PLoS One 2015;10(9):e0138511. doi: https://doi.org/10.1371/journal.pone.0138511
- 10. Lewis TT, Cogburn CD, Williams DR. Self-reported experiences of discrimination and health: scientific advances, ongoing controversies, and emerging issues. Annual Review of Clinical Psychology 2015;11:407-40. doi: https://doi.org/10.1146/annurev-clinpsy-032814-112728
- 11. Goosby BJ, Malone S, Richardson EA, et al. Perceived discrimination and markers of cardiovascular risk among low-income African American youth. American Journal of Human Biology 2015;27(4):546-52. doi: https://doi.org/10.1002/ajhb.22683
- 12. Priest N, Chong S, Truong M, et al. Racial discrimination and socioemotional and sleep problems in a cross-sectional survey of Australian secondary school students. Archives of Disease in Childhood 2020 doi: https://doi.org/10.1136/archdischild-2020-318875
- 13. Yip T. The Effects of Ethnic/Racial Discrimination and Sleep Quality on Depressive Symptoms and Self-Esteem Trajectories Among Diverse Adolescents. J Youth Adolescence 2014;44(2):419-30. doi: http://dx.doi.org/10.1007/s10964-014-0123-x
- 14. Yip T, Cheon YM, Wang Y, et al. Racial Disparities in Sleep: Associations With Discrimination Among Ethnic/Racial Minority Adolescents. Child Development 2020;91(3) doi: https://doi.org/10.1111/cdev.13234
- 15. Garner P, Hopewell S, Chandler J, et al. When and how to update systematic reviews: consensus and checklist. bmj 2016;354:i3507. doi: http://dx.doi.org/10.1136/bmj.i3507
- 16. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. PLoS Medicine 2009;6(7):e1000097. doi: https://doi.org/10.1371/journal.pmed.1000097
- 17. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and metaanalysis protocols (PRISMA-P) 2015: elaboration and explanation. *Bmj* 2016;350 doi: https://doi.org/10.1136/bmj.i4086
- 18. Sawyer SM, Azzopardi PS, Wickremarathne D, et al. The age of adolescence. The Lancet Child & Adolescent Health 2018;2(3):223-28. doi: https://doi.org/10.1016/S2352-4642(18)30022-1
- 19. Priest N, Ferdinand A, Perry R, et al. Mental health impacts of racism and attitudes towards diversity in Victorian schools. A summary of survey findings., 2014.
- 20. Priest N, Williams DR. Racism and Health: A Growing Body of International Evidence, 2015.
- 21. Priest N, Kavanagh A, Bécares L, et al. Cumulative effects of bullying and racial discrimination on adolescent health in Australia. Journal of health and social behavior 2019;60(3):344-61.

- 22. Priest N, Truong M, Chong S, et al. Experiences of racial discrimination and cardiometabolic risk among Australian children. Brain, Behavior, and Immunity 2020
- 23. Pearce J, Rafiq S, Simpson J, et al. Perceived discrimination and psychosis: a systematic review of the literature. Social Psychiatry and Psychiatric Epidemiology 2019:1-22.
- 24. Elias A, Paradies Y. Estimating the mental health costs of racial discrimination. BMC public health 2016;16(1):1205.
- 25. EndNote reference management software [computer program]. Version X9. Philadelphia, United States of America: Clarivate Analytics, 2019.
- 26. Howie Liu, Andrew Ofstad, Nicholas E. Airtable San Francisco, California, United States of America: Howie Liu, Andrew Ofstad, Emmett Nicholas; 2012 [Available from: https://airtable.com/ accessed July 2020.
- 27. Marshall C. Systematic Review Toolbox 2015 [Available from: http://systematicreviewtools.com/index.php accessed July 2020.
- 28. Wells GA, Tugwell P, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses 2019 [Available from: http://www.ohri.ca/programs/clinical epidemiology/oxford.asp accessed July 2020.
- 29. Centre for Research Synthesis and Decision Analysis, University of Bristol, McMaster University, et al. The ROBINS-E tool (Risk of Bias in Non-Randomized Studies-of Exposures) United Kingdom, Canada and The United States of America: University of Bristol, McMaster University and The Environmental Protection Agency; 2018 [Available from: https://www.bristol.ac.uk/population-health-sciences/centres/cresyda/barr/riskofbias/robins-e/ accessed July 2020.
- 30. Bero L, Chartres N, Diong J, et al. The risk of bias in observational studies of exposures (ROBINS-E) tool: concerns arising from application to observational studies of exposures. Systematic reviews 2018;7(1):242. doi: https://doi.org/10.1186/s13643-018-0915-2

Appendix 1- PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol\*

Section and topic	Item No	Checklist item	
ADMINISTRATIVE INFORMA	ATION		
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	
Support:			
Sources	5a	Indicate sources of financial or other support for the review	
Sponsor	5b	Provide name for the review funder and/or sponsor	
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or othe grey literature sources) with planned dates of coverage	
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	

Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of treview (that is, screening, eligibility and inclusion in meta-analysis)	
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$ , Kendall's $\tau$ )	
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	

<sup>\*</sup> It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

**Appendix 2- Search Strategy** 

Search date: 18/7/2020

Database(s): Ovid MEDLINE(R) ALL 1946 to July 16, 2020

#### Search Strategy:

- 1 Prejudice/ or Racism/
- 2 (racism or racial-discriminat\* or racial-prejudice or racist-event\* or racist-episode\* or racial-stereotype\* or race-relatedstress).tw,kf.
- 3 ((discriminat\* or bias\* or prejudic\* or hostil\* or harass\* or bully\* or cyberbull\* or cyber-bull\* or (unfair\* adj1 treat\*) or oppress\*) adj3 (race or racial\* or ethnic\* or cultur\* or religio\* or migrant\* or refugee\* or asylum)).tw,kf.
- 4 (newborn\* or new-born\* or baby or babies or neonat\* or neo-nat\* or infan\* or toddler\* or pre-schooler\* or preschooler\* or kinder or kinders or kindergarten\* or boy or boys or girl or girls or child or children or childhood or pediatric\* or paediatric\* or adolescen\* or youth or youths or teen or teens or teenage\* or school-age\* or schoolage\* or school-child\* or schoolchild\* or school-girl\* or schoolgirl\* or school-boy\* or schoolboy\* or young-person\* or young-people).af.
- 5 Child Welfare/ or pediatric obesity/et, ep, pc
- 6 (Prejudice/ or \*Racism/ or 2 or 3) and 5
- obesity/et, ep, pc or body mass index/ or overweight/pc 7
- 8 Waist-Hip Ratio/
- 9 Blood Pressure/ or Biomarkers/
- 10 Hypertension/et, ep, pc
- 11 exp Cardiovascular Diseases/et, ep, pc
- 12 depression/et, ep, pc or anxiety/et, ep, pc
- 13 Mental Health/
- 14 Stress, Psychological/et, ep, pc
- 15 Sleep/
- 16 exp Sleep Wake Disorders/et, ep, pc
- 17 "Quality of Life"/
- 18 Resilience, Psychological/ or exp adaptation, psychological/
- 19 exp substance-related disorders/et, ep, pc or alcohol-related disorders/et, ep, pc
- 20 smoking/et, ep or exp tobacco smoking/et, ep, pc
- 21 Mental Disorders/et, ep, pc
- 22 Self Concept/
- 23 personal satisfaction/
- 24 exp suicide/et, ep, pc
- 25 conduct disorder/et, ep, pc or aggression/et, ep, pc
- 26 pregnancy outcome/
- 27 (health-care or health-service\* or clinic? or ill-health or wellbeing or well-being or disease\* or illness\* or bmi or body-mass-index or anthropometric\* or WHR or waist-hip-ratio or hypertension or blood-pressure or cardiometabolic or cardio-metabolic or biomarker\* or obese or obesity or overweight or depress\* or anxiety or anxious\* or mental-health or mental-disorder\* or stress or distress\* or suicid\* or sleep or psychosis or tobacco or smoke\* or smoking or drug? or alcohol\* or substance-use or substance-related-disorder\* or resilien\* or self-esteem or self-worth or self-concept or quality-of-life or life-satisfaction or personal-satisfaction or conduct-disorder\* or aggression).tw,kf.
- 28 ((social or behavio\* or emotion\* or developmental\* or psychological\* or learning\*) adj3 (difficul\* or problem\* or delay\* or adjust\*)).tw,kf.
- 29 (((pregnancy or birth or gestation\*) and (outcome\* or preterm or pre-term or premature or small-for-gestational-age)) or low-birthweight or low-birth-weight).tw,kf.
- 30 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 or 26
- 31 \*obesity/et, ep, pc or \*body mass index/ or \*overweight/pc or \*Waist-Hip Ratio/ or (\*Blood Pressure/ or \*Biomarkers/) or \*Hypertension/et, ep, pc or exp \*Cardiovascular Diseases/et, ep, pc or (\*depression/et, ep, pc or \*anxiety/et, ep, pc) or \*Mental Health/ or \*Stress, Psychological/et, ep, pc or \*Sleep/ or exp \*Sleep Wake Disorders/et, ep, pc or \*"Quality of Life"/ or (\*Resilience, Psychological/ or exp \*adaptation, psychological/) or (exp \*substance-related disorders/et, ep, pc or \*alcohol-related disorders/et, ep, pc) or (\*smoking/et, ep or exp \*tobacco smoking/et, ep, pc) or \*Mental Disorders/et, ep, pc or \*Self Concept/ or \*personal satisfaction/ or exp \*suicide/et, ep, pc or (\*conduct disorder/et, ep, pc or \*aggression/et, ep, pc) or \*pregnancy outcome/
- 32 (Prejudice/ or \*Racism/ or 2 or 3) and (27 or 28 or 29 or 31) and 4

- 33 6 or 32
- 34 limit 33 to (comment or editorial or letter)
- 35 33 not 34

## Appendix 3: The ROBINS-E tool (Risk Of Bias In Non-randomized Studies - of Exposures)

Preliminary tool for risk of bia	s in exposure studies (1): At protocol stage	
Specify the research question b	y defining a generic target experiment	
Participants		7
Experimental exposure		
Control exposure		
List the confounding domains i	relevant to all or most studies	
List the possible co-exposures t	that could differ between exposure groups and could have an impact on study outcomes	
List the criteria used to determ	ine the accuracy of exposure measurement	
Factors to consider when evalu	nating health outcome assessment	

# Preliminary tool for risk of bias in exposure studies (2): For each study

Specify a target experiment specific to the	e study.
	Participant
The protocol-specified target experiment fully applies OR	Experimental exposure
Specify the outcome	Control exposure
Specify which outcome is being assessed for risk of harm of exposure.	bias (typically from among those earmarked for the Summary of Findings table). Specify whether this is a proposed benefit of
Is your aim for this study?  to assess the effect of initiating intervention	ı (as in an intention-to-treat analysis)
☐ to assess the effect of initiating and adherin	g to intervention (as in a per-protocol analysis)
□ other (specify)	
Specify the numerical result being assessed	e <b>d</b>
In case of multiple alternative analyses being presen that uniquely defines the result being assessed.	tted, specify the numeric result (e.g. RR = 1.52 (95% CI 0.83 to 2.77) and/or a reference (e.g. to a table, figure or paragraph

# Preliminary consideration of confounders

Complete a row for each important confounding area (i) listed in the review protocol; and (ii) relevant to the setting of this particular study, or which the study authors identified as potentially important.

"Important" confounding areas are those for which, in the context of this study, adjustment is expected to lead to a clinically important change in the estimated effect of the exposure. "Validity" refers to whether the confounding variable or variables fully measure the area, while "reliability" refers to the precision of the measurement (more measurement error means less reliability).

(i) Confounding areas listed in the review protocol					
Confounding area	Measured variable(s)	Is there evidence that controlling for this variable was unnecessary?*	validly and reliably by this variable (or	OPTIONAL: Is adjusting for this variable (alone) expected to move the effect estimate up or down?	
			Yes / No / No information	Favor intervention / Favor control / No information	

(ii) Additional confounding areas relevant to the setting of this particular study, or which the study authors identified as important					
Measured variable(s)	Is there evidence that controlling for this variable was unnecessary?*	Is the confounding area measured validly and reliably by this variable (or these variables)?	OPTIONAL: Is adjusting for this variable (alone) expected to move the effect estimate up or down?		
		Yes / No / No information	Favor intervention / Favor control / No information		
	Measured	Measured Is there evidence that controlling for this	Measured variable(s)  Is there evidence that controlling for this variable was unnecessary?*  Is the confounding area measured validly and reliably by this variable (or these variables)?		

<sup>\*</sup> In the context of a particular study, variables can be demonstrated not to be confounders and so not included in the analysis: (a) if they are not predictive of the outcome; (b) if they are not predictive of exposure; or (c) because adjustment makes no or minimal difference to the estimated effect of the primary parameter. Note that "no statistically significant association" is not the same as "not predictive".

### Preliminary consideration of criteria used to determine the accuracy of measurement of exposure and outcome

Complete a row for each measure listed in the study for the (i) exposure and (ii) outcome. Of the measures listed in the protocol, consider the sensitivity, specificity, and confidence in the methods used in the study.

(i) Exposure measurement method listed in the study					
Method of measurement Measured exposure Is the exposure measured validly and reliably by this method (or these methods)?					
Yes / No / No information					

(ii) Outcome measurement method listed in the study						
Method of measurement Measured outcome Is the outcome measured validly and reliably by this method (or these methods)?						
Yes / No / No information						

### Preliminary consideration of co-exposures

Complete a row for each important co-intervention (i) listed in the review protocol; and (ii) relevant to the setting of this particular study, or which the study authors identified as important.

"Important" co-interventions are those for which, in the context of this study, adjustment is expected to lead to a clinically important change in the estimated effect of the intervention.

(i) Co-exposures listed in the review protocol			
Co-exposure	Is there evidence that controlling for this co-exposure was unnecessary (e.g., because it was not administered)?	Is presence of this co-exposure likely to favor outcomes in the experimental or the control group	
		Favor experimental / Favor comparator / No information	

	Favor experimental / Favor comparator / No information
	Favor experimental / Favor comparator / No information

(ii) Additional co-exposures relevant to the setting of this particular study, or which the study authors identified as important				
Co-exposure	Is there evidence that controlling for this co-exposure was unnecessary (e.g., because it was not administered)?  Is presence of this co-exposure likely to favor outcomes in the experimental or the control group			
	Favor experimental / Favor comparator / No inform			
	Favor experimental / Favor comparator / No informat			
Favor experimental / Favor comparator / No information				

# Risk of bias assessment (cohort-type studies)

	, , , , , , , , , , , , , , , , , , ,		
Bias due to confounding	1.1 Is there potential for confounding of the effect of exposure in this study? If N or PN to 1.1: the study can be considered to be at low risk of bias due to confounding and no further signaling questions need be considered	Y / PY / PN / N	[Description]
	If Y/PY to 1.1, answer 2.1 and 1.3 to determine whether there is a need to assess time-varying confounding:		
	1.2. <b>If Y or PY to 1.1:</b> Was the analysis based on splitting follow up time according to exposure received?	NA / Y / PY / PN / N / NI	[Description]
	If N or PN to 1.2, answer questions 1.4 to 1.6, which relate to baseline confounding		
	1.3. <b>If Y or PY to 1.2</b> : Were exposure discontinuations or switches likely to be related to factors that are prognostic for the outcome?	NA / Y / PY / PN / N / NI	[Description]
	If N or PN to 1.3, answer questions 1.4 to 1.6, which relate to baseline confounding		
	1.4. Did the authors use an appropriate analysis method that adjusted for all the critically important confounding areas?	NA / Y / PY / PN / N / NI	[Description]
	1.5. <b>If Y or PY to 1.4</b> : Were confounding areas that were adjusted for measured validly and reliably by the variables available in this study?	NA / Y / PY / PN / N / NI	[Description]
	1.6. Did the authors avoid adjusting for post-exposure variables?	NA / Y / PY / PN / N / NI	[Description]
	If Y or PY to 1.3, answer questions 1.7 and 1.8, which relate to time-varying confounding		
	1.7. Did the authors use an appropriate analysis method that adjusted for all the critically important confounding areas and for time-varying confounding?		[Description]

23

	1.8. <b>If Y or PY to 1.7</b> : Were confounding areas that were adjusted for measured validly and reliably by the variables available in this study?	NA/Y/PY/PN/N/NI	[Description]
	Risk of bias judgement	Low / Moderate / Serious / Critical / NI	[Support for judgement]
	Optional: What is the predicted direction of bias due to confounding?	Favors experimental / Favors comparator / Unpredictable	[Rationale]
Bias in selection of participants	2.1. Was selection of participants into the study (or into the analysis) based on variables measured after the start of the exposure?	Y / PY / PN / N / NI	[Description]
into the study	If N or PN to 2.1 go to 2.4		
	2.2. <u>If Y/PY to 2.1:</u> Were the post-exposure variables that influenced selection associated with exposure?	Y / PY / PN / N / NI	[Description]
	2.3. If Y/PY to 2.2: Were the post-exposure variables that influenced eligibility selection influenced by the outcome or a cause of the outcome?	NA/Y/PY/PN/N/NI	[Description]
	2.4 Do start of follow-up and start of exposure coincide for most participants?	NA/Y/PY/PN/N/NI	[Description]
	2.5 If Y/PY to 2.2 and 2.3, or N/PN to 2.4: Were adjustment techniques used that are likely to correct for the presence of selection biases?	NA/Y/PY/PN/N/NI	[Description]
	Risk of bias judgement	Low / Moderate / Serious / Critical / NI	[Support for judgement]
	Optional: What is the predicted direction of bias due to selection of participants into the study?	Favors experimental / Favors comparator / Towards null /Away from null / Unpredictable	[Rationale]
Bias in classification	3.1 Is exposure status well defined?	Y / PY / PN / N / NI	[Description]
of exposures	3.2 Did entry into the study begin with start of the exposure?	Y / PY / PN / N / NI	[Description]
	3.3 Was information used to define exposure status recorded prior to outcome assessment?	Y / PY / PN / N / NI	[Description]
	3.4 Could classification of exposure status have been affected by knowledge of the outcome or risk of the outcome?	Y / PY / PN / N / NI	[Description]

	3.5 Were exposure assessment methods robust (including methods used to input data)?		Y / PY / PN / N / NI		[Description]	
Risk of bias judgement			Low / Moderate / Serious / Critical / NI		[Support for judgement]	
	Optional: What is the predicted direction of bias due to measurement of outcomes or exposures?		Favors experimental / Favors comparator / Towards null /Away from null / Unpredictable		[Rationale]	
Bias due to departures from intended	4.1. Is there concern that changes in exposure status occurred among participants?		Y / PY / PN / N / NI		[Description]	
exposures	If your aim for this study is to assess the effect of initiating and adhering to an exposure (as in a per-protocol analysis), answer questions 4.2 and 4.3, otherwise continue to 4.4 if Y or PY to 4.1.					
	4.2. Did many participants switch to other exposures?		Y / F	PY / PN / N / NI	[Descrip	otion]
	4.3. Were the critical co-exposures balanced across exposure groups?		Y / I	PY / PN / N / NI	[Descrip	otion]
		4.4. If NY/PN PY to 4.1, or Y/PY to Were adjustment techniques used that correct for these issues?		NA / Y / PY / PN /	'N/NI	[Description]
Risk of bias judgement		Low / Moderate / Serious / Critical / NI		[Support for judgeme	nt]	
Optional: What is the predicted direction of bias due to departures from the intended exposures?		Favors experimental / Favors comparator / Towards null /Away from null / Unpredictable		[Rationale]		
Bias due to mis	sing data	5.1 Were there missing outcome data?		Y / PY / PN / N / NI		[Description]
		5.2 Were participants excluded due to data on exposure status?	missing	Y / PY / PN / N	/ NI	[Description]
		5.3 Were participants excluded due to missing data on other variables needed for the analysis?		Y / PY / PN / N / NI		[Description]
		5.4 If Y/PY to 5.1, 5.2 or 5.3: Are the of participants and reasons for missing across exposures?		NA / Y / PY / PN /	'N/NI	[Description]
		5.5 If Y/PY to 5.1, 5.2 or 5.3: Were statistical methods used to account data?		NA / Y / PY / PN /	'N/NI	[Description]

	Risk of bias judgement	Low / Moderate / Serious / Critical / NI	[Support for judgement]
	Optional: What is the predicted direction of bias due to missing data?	Favors experimental / Favors comparator / Towards null /Away from null / Unpredictable	[Rationale]
Bias in measurement of outcomes	6.1 Could the outcome measure have been influenced by knowledge of the exposure received?	Y / PY / PN / N / NI	[Description]
	6.2 Was the outcome measure sensitive?	Y / PY / PN / N / NI	[Description]
	6.3 Were outcome assessors unaware of the exposure received by study participants?	Y/PY/PN/N/NI	[Description]
	6.4 Were the methods of outcome assessment comparable across exposure groups?	Y/PY/PN/N/NI	[Description]
	6.5 Were any systematic errors in measurement of the outcome unrelated to exposure received?	Y / PY / PN / N / NI	[Description]
	Risk of bias judgement	Low / Moderate / Serious / Critical / NI	[Support for judgement]
	Optional: What is the predicted direction of bias due to measurement of outcomes?	Favors experimental / Favors comparator / Towards null /Away from null / Unpredictable	[Rationale]
Bias in selection of	Is the reported effect estimate likely to be selected, on the basis of the results, from?		
the reported result	7.1 multiple outcome <i>measurements</i> within the outcome domain?	Y / PY / PN / N / NI	[Description]
	7.2 multiple <i>analyses</i> of the exposure-outcome relationship?	Y / PY / PN / N / NI	[Description]
	7.3 different subgroups?	Y / PY / PN / N / NI	[Description]
	Risk of bias judgement	Low / Moderate / Serious / Critical / NI	[Support for judgement]

	Optional: What is the predicted direction of bias due to selection of the reported result?	Favors experimental / Favors comparator / Towards null /Away from null / Unpredictable	[Rationale]
Overall bias	Risk of bias judgement	Low / Moderate / Serious / Critical / NI	[Support for judgement]
	Optional: What is the overall predicted direction of bias for this outcome?	Favors experimental / Favors comparator / Towards null /Away from null / Unpredictable	[Rationale]